Literature DB >> 17854594

Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients.

Tassilo Volz1, Marc Lutgehetmann, Paul Wachtler, Anna Jacob, Alexander Quaas, John M Murray, Maura Dandri, Joerg Petersen.   

Abstract

BACKGROUND & AIMS: Knowledge of factors regulating transcriptional activity of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) may help in understanding mechanisms of viral decay and how these processes are thwarted in chronically HBV-infected patients.
METHODS: Liver biopsies from 119 treatment-naive chronically infected patients (42 HBeAg-positive and 77 HBeAg-negative) were determined for HBV transcriptional and replicative activity.
RESULTS: Significantly lower median serum HBV DNA (-4 log), intrahepatic HBV DNA (-2 log), and cccDNA (-1 log) amounts were measured in HBeAg-negative versus HBeAg-positive patients. Despite a good correlation found between intrahepatic amounts of progeny virions and serum HBV DNA in all patients, cccDNA levels did not correlate with serum titers in HBeAg-negative individuals. Analysis of HBV RNA transcripts showed that impaired virion productivity in HBeAg-negative individuals was due to lower steady-state levels of pregenomic RNA produced per cccDNA. Interestingly, preS/S RNA levels and serum HBsAg concentrations did not differ between HBeAg-positive and HBeAg-negative patients when normalized for cccDNA contents, showing that subviral particle production was not impaired in HBeAg-negative patients and correlated with cccDNA levels. Although the majority of HBeAg-negative individuals harbored cccDNA with common precore and/or basal core promoter mutations, occurrence of these variants was not responsible for reduced viral replication. Instead, replacement of wild-type cccDNA with core promoter mutants reestablished high virion productivity.
CONCLUSIONS: Lower viremia in HBeAg-negative individuals is not only due to lower cccDNA content but also to impaired virion productivity, which can arise without emergence of HBeAg variants and without affecting HBsAg production.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17854594     DOI: 10.1053/j.gastro.2007.06.057

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  58 in total

1.  IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome.

Authors:  Laura Belloni; Lena Allweiss; Francesca Guerrieri; Natalia Pediconi; Tassilo Volz; Teresa Pollicino; Joerg Petersen; Giovanni Raimondo; Maura Dandri; Massimo Levrero
Journal:  J Clin Invest       Date:  2012-01-17       Impact factor: 14.808

2.  Hepatitis B virus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive and negative infections.

Authors:  Ruy M Ribeiro; Georgios Germanidis; Kimberly A Powers; Bertrand Pellegrin; Paul Nikolaidis; Alan S Perelson; Jean-Michel Pawlotsky
Journal:  J Infect Dis       Date:  2010-11-01       Impact factor: 5.226

3.  Multicenter evaluation of the Elecsys hepatitis B surface antigen quantitative assay.

Authors:  B J Zacher; F Moriconi; S Bowden; R Hammond; S Louisirirotchanakul; P Phisalprapa; T Tanwandee; K Wursthorn; M R Brunetto; H Wedemeyer; F Bonino
Journal:  Clin Vaccine Immunol       Date:  2011-08-31

Review 4.  Genotypes and viral variants in chronic hepatitis B: A review of epidemiology and clinical relevance.

Authors:  Catherine Mn Croagh; Paul V Desmond; Sally J Bell
Journal:  World J Hepatol       Date:  2015-03-27

5.  T5 Exonuclease Hydrolysis of Hepatitis B Virus Replicative Intermediates Allows Reliable Quantification and Fast Drug Efficacy Testing of Covalently Closed Circular DNA by PCR.

Authors:  Bingqian Qu; Yi Ni; Florian A Lempp; Florian W R Vondran; Stephan Urban
Journal:  J Virol       Date:  2018-11-12       Impact factor: 5.103

Review 6.  Potential mechanisms of hepatitis B virus induced liver injury.

Authors:  Mohd Suhail; Hany Abdel-Hafiz; Ashraf Ali; Kaneez Fatima; Ghazi A Damanhouri; Esam Azhar; Adeel Ga Chaudhary; Ishtiaq Qadri
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

7.  Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients.

Authors:  Teerha Piratvisuth; Patrick Marcellin; Matei Popescu; Hans-Peter Kapprell; Vivien Rothe; Zhi-Meng Lu
Journal:  Hepatol Int       Date:  2011-06-24       Impact factor: 6.047

8.  Hepatitis B e-antigen persistency is associated with the properties of HBV-specific CD8 T cells in CHB patients.

Authors:  Guoping Peng; Benyan Luo; Jie Li; Dongjiu Zhao; Wei Wu; Feng Chen; Zhi Chen
Journal:  J Clin Immunol       Date:  2010-12-01       Impact factor: 8.317

9.  Quantitative Levels of Hepatitis B Virus DNA and Surface Antigen and the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Receiving Long-Term Nucleos(t)ide Analogue Therapy.

Authors:  Miwa Kawanaka; Ken Nishino; Jun Nakamura; Takahito Oka; Noriyo Urata; Daisuke Goto; Mitsuhiko Suehiro; Hirofumi Kawamoto; Masatoshi Kudo; Gotaro Yamada
Journal:  Liver Cancer       Date:  2014-03       Impact factor: 11.740

Review 10.  Mechanism of Hepatitis B Virus Persistence in Hepatocytes and Its Carcinogenic Potential.

Authors:  Maura Dandri; Joerg Petersen
Journal:  Clin Infect Dis       Date:  2016-06-01       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.